Selexis SA and Teneobio, Inc. have announced that they have entered into a second services agreement to expand Teneobio’s oncology pipeline of Human Heavy-Chain Antibodies (UniAbs™), a new class of multi-specific biologics. Under the agreement, Teneobio will utilize Selexis’ proprietary SUREtechnology Platform™ to develop research cell banks for three additional preclinical candidates for the potential treatments of B-cell malignancies and prostate cancer.
Founded in 2001, headquartered in Geneve, Switzerland, Selexis SA is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines.
In June 2017, Selexis became part of the JSR Life Sciences group. JSR’s CDMO service offering leverages the full capabilities of Selexis’ proprietary SUREtechnology Platform™ to offer an end-to-end solution to industry.
The modular SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.
Selexis’ global partners are utilizing its technologies to advance more than 100 drug products in clinical development and the manufacture of four commercial products. As part of a comprehensive drug development process, the company’s technologies shorten development timelines and reduce manufacturing risks.
Teneobio, Inc., founded in 2009, headquartered in the San Francisco Bay area, is a biotechnology company developing a new class of biologics, Human Heavy-Chain Antibodies (UniAbs™), for the treatments of cancer, autoimmunity, and infectious diseases. Teneobio’s discovery platform, TeneoSeek, comprises genetically engineered animals (UniRat® and OmniFlic®), next-generation sequencing, bioinformatics and high-throughput vector assembly technologies.
TeneoSeek rapidly identifies large numbers of unique binding molecules specific for therapeutic targets of interest. Versatile antibody variable domains (UniDabs™) derived from UniAbs™ can be assembled into multi-specific and multivalent therapeutic proteins, surpassing limitations of conventional antibody therapeutics.
Teneobio’s “plug-and-play” T-cell engaging platform includes a diverse set of anti-CD3 antibodies for therapeutics with optimal efficacy and reduced toxicity. According to the company, Teneobio plans to file its first IND on its lead program, TNB-383B (anti-BCMAxCD3) for the treatment of multiple myeloma in Q1 of 2019.
Selexis and Teneobio announced their first services agreement in June 2017 to develop research cell banks for multi-specific UniAb candidates for multiple myeloma.
“Selexis’ cell line development technology was very effective in the advancement of Teneobio’s initial bispecific therapeutic lead,” … “We’re excited to continue our work with the Teneobio team as it seeks to bring a new class of oncology biologics to patients. Our partners choose Selexis because we deliver stable and high-performing manufacturing cell lines, while reducing the time, effort and costs associated with their development. The expansion of this relationship with Teneobio is a testament to our expertise and the competitive edge we’re able to deliver to our partners.” – Yemi Onakunle, PhD, MBA, Selexis vice president, licensing and business development
“Beyond TNB-383B, our lead anti-BCMAxCD3 bispecific for the treatment of multiple myeloma, Teneobio is rapidly advancing a pipeline of differentiated multispecific candidates in immuno-oncology. The productivity and effectiveness of our initial work with Selexis made it an easy decision to apply the company’s protein expression platform to additional Teneobio preclinical candidates,” … “We look forward to continuing to work with Selexis as we bring our programs into the clinic.” – Omid Vafa, PhD, MBA, chief business officer at Teneobio, Inc